Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Electrolyte and amino acid supplementation to maintain or restore fluid balance, provide calories from dextrose, and supply essential amino acids for protein synthesis; calcium and other electrolytes support physiological functions.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Provision of calories, amino acids, and electrolytes for parenteral nutrition in patients requiring central venous administration,Short-term maintenance of nitrogen balance in patients with inadequate oral intake
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion at a rate determined by clinical condition and metabolic requirements. Typical adult initial rate: 100 m L/hr, adjusted based on glucose tolerance and fluid status.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as a single entity; amino acids have half-lives ranging from minutes to hours depending on individual amino acid metabolism. Dextrose has a half-life of about 1-2 hours in fasting state, but this formulation is for continuous infusion, so elimination is constant.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Dextrose is metabolized via glycolysis and oxidative pathways; amino acids are catabolized in the liver and tissues; electrolytes are handled by the kidneys.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Renal excretion of amino acids and dextrose metabolites; no significant biliary or fecal elimination. Unused amino acids are deaminated and excreted as urea in urine (approximately 80-90% of nitrogen load). Electrolytes are excreted renally.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids and electrolytes are minimally protein-bound (<5%); no specific binding proteins. Dextrose does not bind to proteins.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Amino acids distribute into total body water (approximately 0.6 L/kg). Dextrose distributes into extracellular fluid (approximately 0.2 L/kg). Electrolytes distribute according to their body compartments (e.g., sodium 0.15 L/kg, potassium 0.4 L/kg).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous only; 100% bioavailability via IV infusion. Not administered via other routes.
Intravenous: 100%.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73m²) due to risk of electrolyte and fluid overload. For mild to moderate impairment (e GFR 30-89 m L/min/1.73m²), monitor serum potassium, calcium, phosphorus, and magnesium; reduce infusion rate as needed.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Use with caution in hepatic impairment; no specific Child-Pugh based dosing. Monitor for signs of hyperammonemia and fluid overload. Avoid in severe hepatic encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Weight-based dosing individualized per metabolic and fluid needs. Typical range: 20-40 m L/hr for neonates and infants, adjusted for age and condition. Maximum glucose infusion rate: 12-14 mg/kg/min for neonates.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Use with caution; monitor renal function and fluid balance. Start at lower infusion rates (e.g., 50-75 m L/hr) and titrate slowly due to reduced renal clearance and higher risk of electrolyte disturbances.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Not for use in patients with severe renal impairment, anuria, or known hypersensitivity to any component. Risk of fluid overload, electrolyte imbalances, and hyperglycemia. Must be administered under medical supervision with monitoring of electrolytes, blood glucose, and acid-base status.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Use caution in patients with renal insufficiency (risk of electrolyte abnormalities), hepatic impairment (risk of hyperammonemia), and diabetes mellitus (risk of hyperglycemia). Monitor for signs of phlebitis or extravasation. Avoid rapid infusion to prevent hyperglycemia and fluid overload.
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Clinically significant hyperglycemia,Severe renal impairment or anuria,Uncompensated heart failure,Pulmonary edema,Health status where intravenous fluid administration is contraindicated
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No direct food interactions as this is an intravenous product. However, oral intake is typically restricted during TPN therapy. Patients receiving TPN may require monitoring of blood glucose and electrolytes if transitioning to oral feeds. Avoid concurrent administration of alcohol due to risk of hypoglycemia.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
No teratogenic risk attributed to components at therapeutic doses; dextrose and electrolytes are essential nutrients. Fetal risks are primarily from maternal metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) which may cause fetal macrosomia, neonatal hypoglycemia, or electrolyte abnormalities if improperly managed. No specific trimester risk increase identified beyond maternal condition.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Components (dextrose, electrolytes) are normally present in breast milk and considered compatible with breastfeeding. No M/P ratio available; risk to infant is low when maternal levels are maintained within physiological ranges.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
No specific dose adjustments required; however, glucose infusion rate may need titration to avoid maternal hyperglycemia due to insulin resistance in pregnancy. Electrolyte requirements may increase, especially potassium and calcium; adjust based on frequent monitoring. Volume status should be carefully managed to avoid fluid overload.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
This is a high-osmolality (850 m Osm/L) parenteral nutrition solution containing 35% dextrose, amino acids, and electrolytes including calcium. MUST be administered via central venous line to prevent thrombophlebitis. Contains sulfite (≤0.3 m Eq/L) as sodium metabisulfite; contraindicated in patients with known sulfite hypersensitivity (e.g., asthmatics). The calcium concentration (approx 4.7 m Eq/L) is low; monitor ionized calcium in critically ill patients. Do not add phosphate to this solution as it may precipitate calcium phosphate. Use within 24 hours of spiking the bag; discard any unused portion. Incompatible with lipid emulsions; administer separately via Y-site with compatible fluids.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This medication is a total parenteral nutrition (TPN) solution that provides complete nutrition intravenously.,It contains dextrose (sugar), amino acids (protein), electrolytes, calcium, and sulfites.,Notify your nurse immediately if you experience difficulty breathing, rash, itching, or swelling, especially if you have asthma or sulfite allergy.,You will need a special central venous catheter (large IV in chest or neck) to receive this solution.,Do not eat or drink anything unless instructed; this solution replaces oral nutrition.,Tell your doctor if you have diabetes, kidney problems, or fluid/electrolyte imbalances.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Electrolyte and amino acid supplementation to maintain or restore fluid balance, provide calories from dextrose, and supply essential amino acids for protein synthesis; calcium and other electrolytes support physiological functions.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion at a rate determined by clinical condition and metabolic requirements. Typical adult initial rate: 100 m L/hr, adjusted based on glucose tolerance and fluid status.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk attributed to components at therapeutic doses; dextrose and electrolytes are essential nutrients. Fetal risks are primarily from maternal metabolic disturbances. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.